title: Oral L-arginine in patients with coronary artery disease on medical management.
abstract: BACKGROUND
  Vascular nitric oxide (NO) bioavailability is reduced in patients with coronary artery disease (CAD). We investigated whether oral L-arginine, the substrate for NO synthesis, improves homeostatic functions of the vascular endothelium in patients maintained on appropriate medical therapy and thus might be useful as adjunctive therapy.
  
  
  RESULTS
  Thirty CAD patients (29 men; age, 67+/-8 years) on appropriate medical management were randomly assigned to L-arginine (9 g) or placebo daily for 1 month, with crossover to the alternate therapy after 1 month off therapy, in a double-blind study. Nitrogen oxides in serum (as an index of endothelial NO release), flow-mediated brachial artery dilation (as an index of vascular NO bioactivity), and serum cell adhesion molecules (as an index of NO-regulated markers of inflammation) were measured at the end of each treatment period. L-Arginine significantly increased arginine levels in plasma (130+/-53 versus 70+/-17 micromol/L, P<0.001) compared with placebo. However, there was no effect of L-arginine on nitrogen oxides (19.3+/-7.9 versus 18. 6+/-6.7 micromol/L, P=0.546), on flow-mediated dilation of the brachial artery (11.9+/-6.3% versus 11.4+/-7.9%, P=0.742), or on the cell adhesion molecules E-selectin (47.8+/-15.2 versus 47.2+/-14.4 ng/mL, P=0.601), intercellular adhesion molecule-1 (250+/-57 versus 249+/-57 ng/mL, P=0.862), and vascular cell adhesion molecule-1 (567+/-124 versus 574+/-135 ng/mL, P=0.473).
  
  
  CONCLUSIONS
  Oral L-arginine therapy does not improve NO bioavailability in CAD patients on appropriate medical management and thus may not benefit this group of patients.
authors.affiliation: Cardiology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892-1650, USA.
authors.forename: A
authors.initials: A
authors.lastname: Blum
authors.forename: L
authors.initials: L
authors.lastname: Hathaway
authors.forename: R
authors.initials: R
authors.lastname: Mincemoyer
authors.forename: W H
authors.initials: WH
authors.lastname: Schenke
authors.forename: M
authors.initials: M
authors.lastname: Kirby
authors.forename: G
authors.initials: G
authors.lastname: Csako
authors.forename: M A
authors.initials: MA
authors.lastname: Waclawiw
authors.forename: J A
authors.initials: JA
authors.lastname: Panza
authors.forename: R O
authors.initials: RO
authors.lastname: Cannon
mesh_terms: D000284:Administration, Oral; D000368:Aged; D001120:Arginine / Q000008:administration & dosage*; D015815:Cell Adhesion Molecules / Q000097:blood; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004311:Double-Blind Method; D004730:Endothelium, Vascular / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000097:blood; D016896:Treatment Outcome
chemical_list: D015815:Cell Adhesion Molecules; D009569:Nitric Oxide; D001120:Arginine